OBJECTIVE: The aim of this study was to compare 99mTc-MDP bone scanning, 18F NaF PET/CT, 18F FDG PET/CT, and whole-body MRI (WBMRI) for detection of known osseous metastases. PATIENTS AND METHODS: This prospective pilot trial (September 2007-April 2009) enrolled 10 participants (5 men, 5 women, 47-81 years old) diagnosed with cancer and known osseous metastases. 18F NaF PET/CT, 18F FDG PET/CT, and WBMRI were performed within 1 month for each participant. RESULTS: The image quality and evaluation of extent of disease were superior by 18F NaF PET/CT compared to 99mTc-MDP scintigraphy in all patients with skeletal lesions and compared to 18F FDG PET/CT in 3 of the patients with skeletal metastases. 18F NaF PET/CT showed osseous metastases where 18F FDG PET/CT was negative in another 3 participants. Extraskeletal metastases were identified by 18F FDG PET/CT in 6 participants. WBMRI with the combination of iterative decomposition of water and fat with echo asymmetry and least-squares estimation, short tau inversion recovery, and diffusion-weighted imaging pulse sequences showed fewer lesions than 18F NaF PET/CT in 5 patients, same number of lesions in 2 patients, and more lesions in 1 patient. WBMRI showed fewer lesions than 18F FDG in 3 patients and same lesions in 6 patients. CONCLUSIONS: Our pilot phase prospective trial demonstrated superior image quality and evaluation of skeletal disease extent with 18F NaF PET/CT compared to 99mTc-MDP scintigraphy and 18F FDG PET/CT, as well as the feasibility of multisequence WBMRI. In addition, 18F FDG PET/CT provided valuable soft-tissue information that can change disease management. Further evaluation of these findings using the recently introduced PET/MRI scanners is warranted.
OBJECTIVE: The aim of this study was to compare 99mTc-MDP bone scanning, 18F NaF PET/CT, 18F FDG PET/CT, and whole-body MRI (WBMRI) for detection of known osseous metastases. PATIENTS AND METHODS: This prospective pilot trial (September 2007-April 2009) enrolled 10 participants (5 men, 5 women, 47-81 years old) diagnosed with cancer and known osseous metastases. 18F NaF PET/CT, 18F FDG PET/CT, and WBMRI were performed within 1 month for each participant. RESULTS: The image quality and evaluation of extent of disease were superior by 18F NaF PET/CT compared to 99mTc-MDP scintigraphy in all patients with skeletal lesions and compared to 18F FDG PET/CT in 3 of the patients with skeletal metastases. 18F NaF PET/CT showed osseous metastases where 18F FDG PET/CT was negative in another 3 participants. Extraskeletal metastases were identified by 18F FDG PET/CT in 6 participants. WBMRI with the combination of iterative decomposition of water and fat with echo asymmetry and least-squares estimation, short tau inversion recovery, and diffusion-weighted imaging pulse sequences showed fewer lesions than 18F NaF PET/CT in 5 patients, same number of lesions in 2 patients, and more lesions in 1 patient. WBMRI showed fewer lesions than 18F FDG in 3 patients and same lesions in 6 patients. CONCLUSIONS: Our pilot phase prospective trial demonstrated superior image quality and evaluation of skeletal disease extent with 18F NaF PET/CT compared to 99mTc-MDP scintigraphy and 18F FDG PET/CT, as well as the feasibility of multisequence WBMRI. In addition, 18F FDG PET/CT provided valuable soft-tissue information that can change disease management. Further evaluation of these findings using the recently introduced PET/MRI scanners is warranted.
Authors: Ida Sonni; Ryogo Minamimoto; Lucia Baratto; Sanjiv S Gambhir; Andreas M Loening; Shreyas S Vasanawala; Andrei Iagaru Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Saima Muzahir; Robert Jeraj; Glenn Liu; Lance T Hall; Alejandro Munoz Del Rio; Timothy Perk; Christine Jaskowiak; Scott B Perlman Journal: Am J Nucl Med Mol Imaging Date: 2015-01-15
Authors: Karsten Beiderwellen; Michael Huebner; Philipp Heusch; Johannes Grueneisen; Verena Ruhlmann; Felix Nensa; Hilmar Kuehl; Lale Umutlu; Sandra Rosenbaum-Krumme; Thomas C Lauenstein Journal: Eur Radiol Date: 2014-06-08 Impact factor: 5.315
Authors: Guru Sonpavde; Gregory R Pond; Melissa Plets; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Amir Goldkorn; Mark G Garzotto; Philip C Mack; Celestia S Higano; Nicholas J Vogelzang; Ian M Thompson; Przemyslaw W Twardowski; Peter J Van Veldhuizen; Neeraj Agarwal; Michael A Carducci; J Paul Monk; David I Quinn Journal: Clin Genitourin Cancer Date: 2017-05-10 Impact factor: 2.872